注射用重组人尿激酶原溶栓治疗STEMI患者的效果及安全性分析

Efficacy and Safety of Recombinant Human Prourokinase for Injection in the Treatment of STEMI Patients

目的分析急性ST段抬高型心肌梗死(STEMI)患者注射用重组人尿激酶原(rhPro-UK)溶栓治疗的效果及安全性。方法回顾分析本院2018年1月-2021年9月收治的50例STEMI患者临床资料,按随机数字表法分组,对照组(n=25)采用尿激酶溶栓治疗,观察组(n=25)采用rhPro-UK溶栓治疗,对比两种治疗方式的差异性。结果治疗后,观察组临床总有效率、冠状动脉再通率和LVEF均高于对照组(P<0.05);观察组CK、CKMB、LVESD、LVEDD、不良反应发生率均低于对照组(P<0.05)。结论STEMI患者注射用rhPro-UK溶栓治疗效果显著,安全性高。

Objective To analyze the effect and safety of thrombolytic therapy with recombinant human prourokinase(rhpro UK)for injection in patients with acute ST segment elevation myocardial infarction(STEMI).Methods The clinical data of 50 patients with STEMI treated in our hospital from January 2018 to September 2021 were retrospectively analyzed.They were grouped according to the random number table method.The control group(n=25)was treated with urokinase thrombolysis and the observation group(n=25)was treated with rhpro UK thrombolysis.The differences between the two treatment methods were compared.Results After treatment,the total clinical effective rate,coronary artery recanalization rate and LVEF in the observation group were higher than those in the control group(P<0.05);The incidence of CK,CKMB,LVESD,LVEDd and adverse reactions in the observation group were lower than those in the control group(P<0.05).Conclusion Rhpro UK thrombolysis for injection is effective and safe in patients with STEMI.